<DOC>
	<DOC>NCT00381758</DOC>
	<brief_summary>This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old. The effects on ADHD symptoms, and any side effects of treatment, were measured for 12 hours after dosing in a simulated classroom. The treatments were blinded and the effects were compared with a Placebo.</brief_summary>
	<brief_title>The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>6 12 years of age, inclusive Have a diagnosis of ADHD Receiving an approved form of MPH (methylphenidate) and have demonstrated clinical improvement during this treatment. IQ below 80. The patient, or a firstdegree relative, has a confirmed diagnosis of Tourette's syndrome or a clinically significant tic disorder. History of seizures (excluding uncomplicated childhood febrile seizures). Myocardial infarction within 3 months of study entry, or has a history of cardiac disease, congenital cardiac abnormality, glaucoma, hyperthyroidism. Comorbid psychiatric diagnosis. Exhibits extreme aggressive behavior or destruction of property, marked anxiety, tension, or agitation.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Metadate CD</keyword>
	<keyword>Concerta</keyword>
	<keyword>COMACS</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder (ADHD)</keyword>
</DOC>